Dash for NASH trips up Gilead, but ‘fatty liver disease’ remains biotech target

Nonalcoholic steatohepatitis, or “fatty liver” disease, is believed to affect some 20 million people in the United States, and a dearth of FDA-approved treatments makes it a big target for drug developers.

Dash for NASH trips up Gilead, but ‘fatty liver disease’ remains biotech target



Source

Some local news is curated - Original might have been posted at a different date/ time! Click the source link for details.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.